Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ATR | Q13535 | 5/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12198438 | 0.86 | ADK (0.52) | MAPTNPC1SMN1; SMN2ATRPRKDC | |
| SCHEMBL6696482 | 0.80 | PIK3CG (0.55) | MAPTATRPIK3CGPRKDCATM | |
| SCHEMBL12198497 | 0.78 | ADK (0.45) | MAPTNPC1SMN1; SMN2ATRPRKDC | |
| SCHEMBL2506364 | 0.78 | ATR (0.42) | MAPTNPC1SMN1; SMN2ATRPRKDC | |
| SCHEMBL934795 | 0.78 | ADORA1 (0.56) | ATRPIK3CGPRKDCATMBCHE | |
| SCHEMBL6701889 | 0.78 | ADORA1 (0.56) | ATRPIK3CGPRKDCATMBCHE | |
| SCHEMBL934749 | 0.76 | ATR (0.52) | ATRPIK3CGFYNPRKDCATM | |
| SCHEMBL13068297 | 0.75 | ROCK1 (0.45) | MAPTNPC1SMN1; SMN2ATRPRKDC | |
| SCHEMBL12839576 | 0.74 | MAPT (0.49) | MAPTNPC1SMN1; SMN2ATRPRKDC | |
| SCHEMBL10726997 | 0.74 | FYN (0.58) | MAPTNPC1SMN1; SMN2FYNSMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454261-B1 | IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE | UNIV SIENA (IT) | 2014-11-19 | — | — | EP | disclosed |
| US-8546147-B2 | Imidazo[1,2-α]pyrazin-3(7H)-one derivatives bearing a new electron-rich structure | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2013-10-01 | — | — | US | disclosed |
| US-20120171703-A1 | IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2012-07-05 | — | — | US | disclosed |
| EP-2454261-A1 | IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE | Universita Degli Studi di Siena (IT) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011007314-A1 | IMIDAZO[1,2-α]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE | UNIVERSITÀ DEGLI STUDI DI SIENA (IT) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171703-A1 | IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE | GLB1, NDUFV1, IK | MAPT 4536/4885NPC1 1816/4885SMN1; SMN2 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.